Tirzepatide Dramatically Improves Waist-to-Height Ratio in Adults with Obesity

Obesity and overweight are major global health concerns, significantly increasing the risk of cardiovascular disease, type 2 diabetes, and other metabolic complications. While Body Mass Index (BMI) is a common measure, waist-to-height ratio (WHtR) is increasingly recognized as a superior indicator of central adiposity and associated health risks. Previous studies have shown tirzepatide is highly effective for weight loss, but the specific impact of tirzepatide on shifting individuals out of high-risk WHtR categories has not been thoroughly evaluated.

Treatment with tirzepatide led to substantial improvements in WHtR across all dose groups compared to placebo. At 72 weeks, 85% of participants receiving tirzepatide 15 mg achieved a healthy WHtR (<0.5), compared to only 29% in the placebo group (p<0.001). The most significant finding was that 78% of participants in the tirzepatide 10 mg group and 71% in the 5 mg group also reached a healthy WHtR, demonstrating a dose-dependent and highly effective reduction in central adiposity. Furthermore, the average WHtR decreased by 18.5% in the 15 mg group, 16.2% in the 10 mg group, and 14.1% in the 5 mg group, versus a mere 3.2% reduction with placebo (p<0.001 for all active groups vs. placebo). This indicates a profound shift from high-risk to healthy WHtR categories.